Skye Bioscience is a clinical stage biopharmaceutical company based in San Diego, California, focused on developing novel medicines that modulate G-protein-coupled receptors, particularly targeting the endocannabinoid system to treat metabolic and neurological disorders. The company's lead program, nimacimab, is a negative allosteric modulating antibody designed to inhibit peripheral cannabinoid receptor 1, currently in Phase 2 development for obesity treatment. In combination with existing weight loss therapies, nimacimab has demonstrated meaningful efficacy in clinical trials. The company's pipeline also includes SBI-100 Ophthalmic Emulsion, a cannabinoid receptor agonist in development for glaucoma and ocular hypertension. Skye's approach aims to address gaps in care left by current weight loss medications by targeting well-established biological pathways with strong human evidence. The company pursues partnerships with specialist life science investors and is advancing its clinical programs toward potential regulatory milestones in treating obesity and related metabolic conditions.